CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
MetadataShow full item record
CitationSengupta, S., R. Rojas, A. Mahadevan, E. Kasper, and S. Jeyapalan. 2015. “CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer.” Oxford Medical Case Reports 2015 (4): 254-257. doi:10.1093/omcr/omv010. http://dx.doi.org/10.1093/omcr/omv010.
AbstractNervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast cancer with brain metastases.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23993583
- HMS Scholarly Articles